Executives
?
Tarriff Scott
CEO
Eagle Pharmaceuticals, Inc.
US, Woodcliff Lake [HQ]
CIK
1469124
Data Source
We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.
Latest Information
Shares :
587,311
Price per Share :
$0.62
Equivalence :
$364,132.82
Transaction History
-
S587,311 Shares After TransactionValue : $11,734,473.78Sold $299,700.00Transaction Date : 05/16/23
-
Footnotes
-
-
Footnotes:#1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.7454 to $20.53 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.#2 This report reflects an adjustment to the Reporting Person's direct holdings to exclude shares incorrectly included in prior reports as directly held and to reflect such shares as held indirectly through the Tarriff 2016 Generation Skipping Exempt Family Trust DTD 12/28/2016 (the "Trust").
-
S556,141 Shares After TransactionValue : $7,685,868.62Sold $150,983.50Transaction Date : 11/01/23
-
Footnotes
-
-
Footnotes:#1 These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.#2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.64 to $14.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).#3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.20 inclusive.
-
S545,447 Shares After TransactionValue : $7,565,349.89Sold $148,325.78Transaction Date : 11/02/23
-
Footnotes
-
-
Footnotes:#1 These transactions were made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 15, 2023.#2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.64 to $14.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3).#3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.20 inclusive.
-
A1,579,706 Shares After TransactionValue : $n/a$0.0Transaction Date : 02/28/22
-
Footnotes
-
-
Footnotes:#1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's common stock upon vesting of the unit. The shares issuable in respect of such RSUs shall vest with respect to 25% of the shares of common stock on each of the one, two, three and four-year anniversaries of February 28, 2022, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.
-
F1,575,879 Shares After TransactionValue : $46,110,219.54$111,978.02Transaction Date : 01/05/23
-
Footnotes
-
-
Footnotes:#1 The disposition reported on this Form 4 represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the settlement of restricted stock units.